Health Policy Archive — Page 7 of 7

July 25, 2019

Private practice physicians less likely to maintain EHRs

A new study finds private practice physicians are less likely to maintain electronic health records.

By Jake Lowary
July 11, 2019

New data reveals highly variable staffing at nursing homes

Researchers who analyzed payroll-based staffing data for U.S. nursing homes discovered large daily staffing fluctuations, low weekend staffing and daily staffing levels that often fall well below the expectations of the Centers for Medicare and Medicaid Services (CMS), all of which can increase the risk of adverse events for residents.

By Jill Clendening
July 1, 2019

Study shows some generics can cost Medicare recipients more than brand-name drugs

Medicare Part D enrollees may pay more out of pocket for high-priced specialty generic drugs than their brand-name counterparts, according to new research by health policy experts at Vanderbilt University Medical Center and the University of North Carolina at Chapel Hill.

By Jake Lowary
August 16, 2018

Vanderbilt study explores how dual-eligible beneficiaries spend

While there has been much effort to control spending for individuals eligible for both Medicaid and Medicare in the United States, for the first time a team of Vanderbilt health policy researchers have analyzed spending trends for this population over a multiyear period in order to gain a much clearer understanding of exactly how much is being spent and by whom.

By Jill Clendening
August 9, 2018

Study to explore how rising medication costs impact elderly

As both drug prices and out-of-pocket expense for prescription medications continue to climb, a team of Health Policy experts at Vanderbilt University School of Medicine (VUSM) have received a grant to determine if these factors are causing older Americans enrolled in Medicare Part D for medication coverage to delay or never fill their prescriptions.

By Jill Clendening
(iStock)
May 9, 2018

Study finds generic options offer limited savings for expensive drugs

Generic drug options did not reduce prices paid for the cancer therapy imatinib (Gleevec), according to a Health Affairs study released this week.

By Craig Boerner